Extracranial Metastases in Glioblastoma, IDH-Wildtype: A Case Series
Diagnostics · 05.04.2026 · 16 (7) · 1094
DOI: 10.3390/diagnostics16071094 ↗Kurz gefasst
Fallbericht in der Zeitschrift Diagnostics, online erschienen am 05.04.2026. Verfasst von Valèria Richart und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology, Hospital Clinic de Barcelona, 08036 Barcelona, Spain. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Extracranial metastasis (EM) from glioblastoma (GB), IDH-wildtype (WHO CNS 2021 grade 4) is rare and often under-recognized, yet it has immediate implications for staging and management. We report a case series integrating advanced neuroimaging, whole-body imaging, and pathology/biomarkers to characterize imaging–pathology correlates of EM and highlight practical clinical triggers that should prompt systemic evaluation. Case presentation: We report three patients with adult-type, IDH-wildtype GB who developed EM confirmed by cytology/histology and/or concordant multimodality imaging. Brain MRI (1.5T/3T) demonstrated aggressive primary tumors with qualitative elevation of DSC-perfusion and frequent tumor–surface contact (dural, ependymal/leptomeningeal contact). Intratumoral susceptibility signal reached grade 3 where assessed. All patients underwent surgical resection followed by temozolomide-based chemoradiation; two received fotemustine and bevacizumab, and one underwent re-irradiation. EM presented with clinical triggers including severe axial/back pain, palpable cervical masses, and/or cytopenias. Initial EM sites were bone marrow/vertebrae (n = 1) and cervical lymph nodes (n = 2); staging revealed additional osseous disease in both nodal cases and a small pulmonary nodule in one. Nodal and osseous lesions were FDG-avid on 18F-FDG PET/CT. OLIG2-positive cytology confirmed cervical nodal metastases, and bone marrow aspiration with GFAP/OLIG2 positivity confirmed medullary infiltration. All tumors shared a molecular profile of TERT-promoter mutation, ATRX wild-type, TP53 mutation, and MGMT-promoter methylation. Despite attempts at second- and third-line therapies, disease progression was rapid, and all patients succumbed within 8–16 months of diagnosis.
Discussion
This series underscores that EM can occur despite MGMT-promoter methylation and supports the concept of heterogeneous metastatic phenotypes in GB. Our cases reinforce that new axial/back pain or hematologic abnormalities may signal osseous or marrow involvement, and necrotic cervical lymphadenopathy in GB patients warrants dedicated imaging and tissue confirmation with glial markers. Integrating brain MRI features (high perfusion, surface contact, susceptibility burden) with FDG-PET/CT and targeted cytology/pathology can expedite diagnosis and inform multidisciplinary care.
Conclusions
EM can arise despite MGMT-promoter methylation in IDH-wildtype GBM. Imaging red flags (high perfusion, surface contact, necrotic/FDG-avid cervical nodes) and clinical cues (axial pain, cytopenias, neck masses) should prompt early systemic staging (CT/PET-CT) and targeted tissue confirmation to advance management.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Radiology, Hospital Clinic de Barcelona, 08036 Barcelona, Spain.
- Department of Oncology, Hospital Clinic de Barcelona, 08036 Barcelona, Spain.
- Department of Pathology, Biomedical Diagnostic Center (CDB), Hospital Clinic de Barcelona, University of Barcelona, and Neurological Tissue Bank of the Biobank, FCRB/IDIBAPS, 08036 Barcelona, Spain.
- Radiotherapy Oncology Service, Hospital Clinic de Barcelona, 08036 Barcelona, Spain.
- Department of Neurosurgery, Hospital Clinic de Barcelona, 08036 Barcelona, Spain.
ORCID-Profile: Valèria Richart, Iban Aldecoa, Estela Pineda, Izaskun Valduvieco, José Juan González, Laura Oleaga, Sofía González-Ortiz
Zitieren
APA
Richart, V., García de Herreros, M., Mora, J. A., Pineda, C., Aldecoa, I., Pineda, E., Valduvieco, I., González, J. J., Oleaga, L., & González-Ortiz, S. (2026). Extracranial Metastases in Glioblastoma, IDH-Wildtype: A Case Series. Diagnostics, 16(7), 1094. https://doi.org/10.3390/diagnostics16071094
Vancouver
Richart V, García de Herreros M, Mora JA, Pineda C, Aldecoa I, Pineda E, et al. Extracranial Metastases in Glioblastoma, IDH-Wildtype: A Case Series. Diagnostics. 2026;16(7):1094. doi:10.3390/diagnostics16071094
BibTeX
@article{Richart2026,
author = {Richart, Valèria and García de Herreros, Marta and Mora, Juan Andrés and Pineda, Camilo and Aldecoa, Iban and Pineda, Estela and Valduvieco, Izaskun and González, José Juan and Oleaga, Laura and González-Ortiz, Sofía},
title = {Extracranial Metastases in Glioblastoma, IDH-Wildtype: A Case Series},
journal = {Diagnostics},
year = {2026},
volume = {16},
number = {7},
pages = {1094},
doi = {10.3390/diagnostics16071094}
}
EUVIMED